Dyne Therapeutics reports larger-than-expected Q2 net loss per share
DYN•Outlook
- Dyne expects potential U.S. launch of z-rostudirsen in Q1 2027, pending FDA approval
- Company plans topline data for z-basivarsen ACHIEVE trial in Q1 2027
- Dyne projects cash runway into Q2 2028
Overview
- U.S. neuromuscular drug developer's Q2 net loss per share was larger than analyst expectations
- R&D and G&A expenses rose on higher manufacturing, clinical costs and launch preparations
- Company completed $431 mln public offering; expects cash runway into Q2 2028
Result Drivers
- Higher clinical costs - Co said increased R&D expenses were mainly due to higher manufacturing activity and clinical costs for z-rostudirsen and z-basivarsen
- Launch preparations - Co attributed higher G&A expenses to increased costs in preparation for the potential launch of z-rostudirsen
Analyst Coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Related News
Franklin BSP Realty Trust Q2 net income falls, repurchased 1.8 mln shares
FBRT•
European Commission Authorizes Pfizer And Biontech Xfg-Adapted Covid-19 Vaccine In The European Union
PFE•
